Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 3/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 14/20 | 0.45 |
| ▸ | WNT1 | P04628 | 12/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17452986 | 0.91 | ROCK2 (0.50) | ROCK1DYRK1AWNT1KCNH2KDM4E | |
| SCHEMBL19902532 | 0.83 | DYRK1A (0.46) | ROCK1DYRK1AWNT1KCNH2 | |
| SCHEMBL19902494 | 0.83 | ROCK1 (0.48) | ROCK1DYRK1AKDM4ESMN1; SMN2HSD17B10 | |
| SCHEMBL19902644 | 0.83 | ROCK1 (0.56) | ROCK1KDM4ESMN1; SMN2HSD17B10NPC1 | |
| SCHEMBL19902392 | 0.76 | ROCK1 (0.43) | ROCK1DYRK1A | |
| SCHEMBL17452987 | 0.75 | ROCK2 (0.50) | ROCK1DYRK1AWNT1KCNH2 | |
| SCHEMBL19902638 | 0.75 | ROCK1 (0.43) | ROCK1KDM4ESMN1; SMN2HSD17B10NPC1 | |
| SCHEMBL17452902 | 0.75 | ROCK2 (0.53) | ROCK1KDM4ESMN1; SMN2HSD17B10NPC1 | |
| SCHEMBL17452989 | 0.75 | ROCK2 (0.51) | ROCK1DYRK1AKDM4ESMN1; SMN2HSD17B10 | |
| SCHEMBL17452959 | 0.74 | ROCK2 (0.56) | ROCK1KDM4ESMN1; SMN2HSD17B10NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180155296-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2018-06-07 | — | — | US | disclosed |
| US-9902702-B2 | Spirocycloheptanes as inhibitors of rock | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155296-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | ROCK1, MYLK, ROCK2 | ROCK1 1/4885DYRK1A 874/4885WNT1 974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.